Hepatitis C virus infection

This pilot study is testing whether a 4-week course of two antiviral drugs—sofosbuvir plus glecaprevir/pibrentasvir—can cure chronic hepatitis C in people who have not been treated before and have only mild liver scarring. Participants who relapse after the short treatment will r…

This study tests a collaborative care model where pharmacists, doctors, and patient navigators work together to provide hepatitis C treatment to people who use drugs and live in supportive housing. 444 participants will be randomly assigned to either this model or usual care. The…

This study tests whether a low-barrier hepatitis C treatment program can help people in jail start and finish their medication more easily. Forty adults awaiting trial at the Rhode Island Department of Corrections will receive a 12-week course of the antiviral drug Epclusa. If re…

This trial tests whether treating hepatitis C in primary care clinics, with non-specialist doctors, works as well as the standard specialist care in Brazil. It also evaluates the use of rapid tests and self-testing to find more people with the infection. The goal is to see if a s…

This study is testing the safety and drug levels of glecaprevir/pibrentasvir, a hepatitis C treatment, in 30 pregnant women with or without HIV. The goal is to see how the drug works during pregnancy and to monitor the health of both mothers and their infants up to 10 weeks after…

This study tests a drug called foscenvivint in people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. Participants receive the drug once a week for 24 weeks. Researchers will check if the drug improves liver function and is safe to use.

This study looks at whether starting hepatitis C treatment during pregnancy is feasible and acceptable for women who have used drugs. Fifty pregnant adults with hepatitis C will take glecaprevir-pibrentasvir daily for 56 days. Researchers will track how well participants stick to…

This project aims to make hepatitis C testing and treatment easier for people who visit drug treatment clinics and needle exchange programs. Researchers will work with clinics across New South Wales, Australia, to help more people start treatment. The study includes up to 6,000 a…

This program offers eltrombopag to patients with serious or life-threatening thrombocytopenia (low platelet counts) who have no other treatment options and cannot join a clinical trial. A licensed physician must request the drug, and the potential benefit must outweigh the risks.…

This study tests whether a daily nutritional supplement containing resveratrol, quercetin, taurine, inulin, and whey protein can improve liver function and quality of life in adults with liver disease from chronic hepatitis C. Over 12 weeks, 26 participants will take either the s…

This study tests whether giving patients donor-derived immune cells (VSTs) on a regular schedule can prevent dangerous viral infections after a stem cell transplant. 180 participants will be randomly assigned to receive VSTs either on a fixed schedule or only when a virus is dete…

This study looks at the best time to give hepatitis C medication to people without HCV who receive a kidney from an HCV-positive donor. One group starts the drug just before transplant and takes it for only 2 weeks; the other starts after transplant and takes it for 12 weeks. The…

This study tracks 500 people who received a heart transplant from a donor with hepatitis C. Researchers want to see if using these organs is safe and works well. They will measure cure rates for hepatitis C, organ rejection, and survival after one year.

This study tests whether specially grown donor immune cells (viral-specific T-cells) can safely treat viral infections that often occur after a stem cell transplant. These infections can be serious and sometimes don't respond to standard antiviral drugs. The approach aims to boos…

This large Australian study is testing whether offering a finger-stick point-of-care test for hepatitis C can increase diagnosis and treatment rates. Adults at risk for hepatitis C will be offered the rapid test at services they already use. Those who test positive for the virus …

This large Australian study is testing whether offering finger-stick point-of-care testing for hepatitis C in community settings—like drug treatment clinics, homeless shelters, and prisons—can increase the number of people diagnosed and linked to treatment. The study will include…

This study collects blood samples from healthy people, those with benign diseases, and cancer patients to develop a multi-analyte blood test. The test looks for DNA methylation markers that may indicate the presence of various cancers, especially liver cancer. Researchers aim to …

This study aims to see if a dried blood spot test can effectively screen drug users for hepatitis B, hepatitis C, and AIDS. Researchers will enroll 500 former or active drug users. The goal is to find a simpler way to detect these infections in a hard-to-reach population.

This study is testing a new medical device called MagIA IBC that uses a single drop of blood from a finger prick to screen for HIV, hepatitis B, and hepatitis C at the same time. Researchers will enroll 252 adults who are known or suspected to have one of these infections. The go…

This study tests a new device called MagIA H3S that can screen for HIV, hepatitis B, hepatitis C, and syphilis using a single blood sample. Researchers will enroll about 2,950 people in Ivory Coast and Kenya to see how accurate the device is compared to standard lab tests. If it …

This study tests whether a 'practice coaching' program can help opioid treatment clinics offer more HIV and hepatitis C testing to their patients. Clinics are randomly assigned to receive either coaching focused on HIV testing, coaching that adds hepatitis C testing, or just info…

This study combines peer navigation (trained community members) with mobile health tools to help gay, bisexual, and transgender people in rural Appalachia access HIV, STI, and hepatitis C testing and prevention services. About 141 participants will be split into two groups: one g…

This pilot study tests whether a peer-driven program can help people who inject drugs in Baltimore reduce their risk of HIV, hepatitis C, and overdose. Researchers will identify high-risk injection settings and train peers to promote safer practices, like carrying naloxone and av…

This study tests a program called Mobile Enhanced Prevention Support (MEPS) for people recently released from jail or prison who have substance use disorders. The program pairs participants with a peer mentor, offers cash incentives for using health services, and provides a smart…

This early-phase study tests whether anakinra, a drug that blocks inflammation, can make the heart more sensitive to inotropes (medicines that strengthen heart contractions) in people with end-stage heart failure. If successful, patients might need lower, safer doses of inotropes…

This study aims to learn more about liver diseases like hepatitis B, C, and D by observing up to 8,050 participants over time. Participants will have yearly check-ups, blood and urine tests, and liver ultrasounds. Some may be offered experimental treatments if they qualify. The g…

This study looks at whether a rapid fingerstick test that gives results in 10-20 minutes can help more people get screened for HIV, hepatitis C, and syphilis during mobile clinic visits. About 200 patients of the WVU Street Medicine team can choose the rapid test, a traditional b…

This study is testing whether a quick finger-stick test can help find more people with hepatitis C and get them into treatment. About 60,000 adults at risk for hepatitis C will take the test at clinics, shelters, or prisons. The study itself does not provide treatment, but will c…

This study aims to collect samples and medical information from people of all ages who have or have been exposed to viral infections, including COVID-19 and herpes. Researchers want to understand how viruses affect healthy individuals versus those with weakened immune systems. Pa…

This study tests a smartphone app designed to teach emergency room patients about hepatitis C (HCV) and help them connect to follow-up care. Researchers will enroll 308 HCV-positive patients at an urban ER. The app provides personalized information on liver health and care option…

This study aims to find undiagnosed cases of advanced liver fibrosis and viral hepatitis B and C in the general population of Seine Saint Denis, France. Using a combination of rapid diagnostic tests and a portable liver stiffness scanner (FibroScan), researchers will screen 600 a…

This study uses a device called FibroScan to measure liver stiffness and fat content in people with liver disease. The scan is non-invasive, like an ultrasound, and takes only a few minutes. Researchers aim to build a large database of these measurements to help improve future di…

This study in South-East Austria looks at past lab results to find people with hepatitis B, C, or D who may not know they have it. Researchers will invite these individuals to a clinic to discuss treatment options. The goal is to connect them to care and track how many get cured,…

This study is looking at 1,000 liver transplant recipients to see if testing their blood, urine, and tissue samples can detect early signs of chronic kidney disease, acute rejection, or hepatitis C. The goal is to find simple biomarkers that could lead to earlier treatment and fe…

This study looks back at medical records of 2,000 people with hepatitis C who took an 8-week course of glecaprevir/pibrentasvir (G/P). The goal is to see how safe and effective the treatment is for those also taking prescription or illegal drugs. Researchers will track side effec…

This study tests whether a very brief, persuasive message—delivered by a video or a counselor—can increase HIV and hepatitis C testing among emergency room patients who initially said no. About 2,000 adults who speak English or Spanish and haven't been tested in the past year wil…

This study looks at how common certain infections are among 250 asylum seekers living in reception centers in Italy. Participants must be adults who arrived in Italy between 2 and 36 months ago. The goal is to better understand infection rates to improve health screening and care…

This study collects DNA from 1200 patients receiving routine care at the University of Chicago. Researchers look for genetic differences that might affect how well a drug works or how likely it is to cause side effects. The goal is to see if giving this genetic information to doc…

This study looks at how the drug bulevirtide changes gut bacteria and bile acids in people with hepatitis delta (a serious liver infection). Researchers will follow 20 patients for 48 weeks, collecting stool and blood samples to see how these changes relate to liver health. The g…

This study is a long-term project that collects health information from 30,000 HIV patients at 15 clinics in France. The goal is to track how well HIV treatments are working, monitor changes in the disease over time, and understand related health issues like hepatitis C. No new t…

This study collects blood and tissue samples from 800 people with chronic liver disease or liver cancer. Researchers will use these samples to create lab models, such as cell clusters and mouse tumors, to study these diseases and test new treatments. The goal is to improve unders…

This study looks at how to get more people in Canadian federal prisons to use needle exchange programs, which can help stop the spread of HIV and hepatitis C. Researchers will work in nine prisons, including five women's prisons, to find out what helps or hinders program use and …

This study looks at medical records from 15,000 people to see how chronic liver diseases (like hepatitis, fatty liver, and cirrhosis) are linked to other health problems. Researchers will track new cases of liver cancer and complications over time. The goal is to better understan…